Skip to main content
Ovarian Cancer
Phase 2 Placebo-Controlled Study to Assess the Efficacy/Safety of Farletuzumab plus Chemotherapy in Women with Low CA-125 Platinum-Sensitive Ovarian Cancer
Read More
Ovarian Cancer
Phase 2 APPROVE Trial of Apatinib plus Pegylated Liposomal Doxorubicin (PLD) versus PLD for Platinum-Resistant Recurrent Ovarian Cancer
Read More
Ovarian Cancer
Long-Term Safety and Secondary Efficacy End Points in the ENGOT-OV16/NOVA Phase 3 Trial of Niraparib in Recurrent Ovarian Cancer
Read More
Ovarian Cancer
Phase 1 Trial of Ribociclib (LEE-011) with Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer
Read More
Ovarian Cancer
ARIEL4 Results of Rucaparib versus Chemotherapy in Patients with Advanced, Relapsed Ovarian Cancer and a Deleterious BRCA Mutation
Read More
Ovarian Cancer
Progression-Free Survival Benefit from Maintenance Olaparib in Patients with Platinum-Sensitive Relapsed Ovarian Cancer by BRCA and Other Homologous Recombination Repair Gene Mutation Status (ORZORA Trial)
Read More
Ovarian Cancer
Olaparib Treatment in Patients with Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency Status: Secondary Safety Results from the Phase 2 LIGHT Study
Read More
Ovarian Cancer
5-Year Follow-Up of the SOLO1/GOG 3004 Trial of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation
Read More
Ovarian Cancer
Subgroup Analysis of the ARIEL4 Study of the Effect of Platinum Sensitivity on Efficacy of Rucaparib versus Chemotherapy for BRCA-Mutated, Advanced, Relapsed Ovarian Carcinoma
Read More
Ovarian Cancer
Analysis of the Phase 3 PAOLA-1/ENGOT-ov25 Trial by Disease Stage in Patients with Homologous Recombination Deficiency–Positive Newly Diagnosed Advanced Ovarian Cancer Receiving Bevacizumab with Olaparib/Placebo Maintenance
Read More
Page 68 of 197
Results 671 - 680 of 1963